Market Cap (In USD)
19.14 Million
Revenue (In USD)
-
Net Income (In USD)
-1.61 Million
Avg. Volume
1260.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.072-0.4
- PE
- -
- EPS
- -
- Beta Value
- 0.814
- ISIN
- US4525364026
- CUSIP
- 452536204
- CIK
- 822411
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Irach B. Taraporewala B.S., M.S., Ph.D.
- Employee Count
- -
- Website
- https://www.eompharma.com
- Ipo Date
- 2021-01-08
- Details
- Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
More Stocks
-
PSHG
-
HEAL
-
WFHG
-
NATURALNatural Biocon (India) Limited
NATURAL
-
300080
-
GSL-PBGlobal Ship Lease, Inc.
GSL-PB
-
ALMDPMedesis Pharma S.A.
ALMDP
-
BALD-BFastighets AB Balder (publ)
BALD-B